A survey of the effects of sivelestat sodium administration on patients with postoperative respiratory dysfunction

Hiroshi Saeki, Masaru Morita, Noboru Harada, Norifumi Harimoto, Shigeyuki Nagata, Mitsuhiro Miyazaki, Tadashi Koga, Eiji Oki, Yoshihiro Kakeji, Yoshihiko Maehara

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: To clarify the clinical significance of sivelestat sodium (SIV) administration, we surveyed the status of 40 patients treated with SIV for respiratory dysfunction following surgery. Methods: The subjects were patients who received SIV administration due to systemic inflammatory response syndrome (SIRS) and respiratory dysfunction (PaO2/FIO2 ratio ≥300 mmHg) after surgery at the Department of Surgery and Science, Kyushu University, and related facilities between April and December 2008. Results: The most frequent underlying condition was perforation of the digestive tract, followed by cancer of the upper digestive organs. The main causes of SIRS were surgical stress and infection. The mean P/F ratio at the initiation of SIV administration was 185.5 ± 72.0 mmHg. The ratio increased, and the number of SIRS-related factors decreased with time after SIV administration. Sivelestat sodium was administered within 24 h after the onset of respiratory dysfunction in 87.5% of the patients, and the survival rate at 28 days after the initiation of SIV administration was 90.0%. Conclusion: Our findings suggest that multidisciplinary postoperative management, including the administration of SIV, during the early phase after the onset of respiratory dysfunction leads to improvements in respiratory function and survival.

Original languageEnglish
Pages (from-to)1034-1039
Number of pages6
JournalSurgery today
Volume40
Issue number11
DOIs
Publication statusPublished - Nov 1 2010

Fingerprint

Sodium
Systemic Inflammatory Response Syndrome
Surveys and Questionnaires
sivelestat
Gastrointestinal Tract
Survival Rate
Survival
Infection
Neoplasms

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

A survey of the effects of sivelestat sodium administration on patients with postoperative respiratory dysfunction. / Saeki, Hiroshi; Morita, Masaru; Harada, Noboru; Harimoto, Norifumi; Nagata, Shigeyuki; Miyazaki, Mitsuhiro; Koga, Tadashi; Oki, Eiji; Kakeji, Yoshihiro; Maehara, Yoshihiko.

In: Surgery today, Vol. 40, No. 11, 01.11.2010, p. 1034-1039.

Research output: Contribution to journalArticle

Saeki, H, Morita, M, Harada, N, Harimoto, N, Nagata, S, Miyazaki, M, Koga, T, Oki, E, Kakeji, Y & Maehara, Y 2010, 'A survey of the effects of sivelestat sodium administration on patients with postoperative respiratory dysfunction', Surgery today, vol. 40, no. 11, pp. 1034-1039. https://doi.org/10.1007/s00595-010-4296-y
Saeki, Hiroshi ; Morita, Masaru ; Harada, Noboru ; Harimoto, Norifumi ; Nagata, Shigeyuki ; Miyazaki, Mitsuhiro ; Koga, Tadashi ; Oki, Eiji ; Kakeji, Yoshihiro ; Maehara, Yoshihiko. / A survey of the effects of sivelestat sodium administration on patients with postoperative respiratory dysfunction. In: Surgery today. 2010 ; Vol. 40, No. 11. pp. 1034-1039.
@article{e38b3c2cb12b449ab6e0441dc17b98ef,
title = "A survey of the effects of sivelestat sodium administration on patients with postoperative respiratory dysfunction",
abstract = "Purpose: To clarify the clinical significance of sivelestat sodium (SIV) administration, we surveyed the status of 40 patients treated with SIV for respiratory dysfunction following surgery. Methods: The subjects were patients who received SIV administration due to systemic inflammatory response syndrome (SIRS) and respiratory dysfunction (PaO2/FIO2 ratio ≥300 mmHg) after surgery at the Department of Surgery and Science, Kyushu University, and related facilities between April and December 2008. Results: The most frequent underlying condition was perforation of the digestive tract, followed by cancer of the upper digestive organs. The main causes of SIRS were surgical stress and infection. The mean P/F ratio at the initiation of SIV administration was 185.5 ± 72.0 mmHg. The ratio increased, and the number of SIRS-related factors decreased with time after SIV administration. Sivelestat sodium was administered within 24 h after the onset of respiratory dysfunction in 87.5{\%} of the patients, and the survival rate at 28 days after the initiation of SIV administration was 90.0{\%}. Conclusion: Our findings suggest that multidisciplinary postoperative management, including the administration of SIV, during the early phase after the onset of respiratory dysfunction leads to improvements in respiratory function and survival.",
author = "Hiroshi Saeki and Masaru Morita and Noboru Harada and Norifumi Harimoto and Shigeyuki Nagata and Mitsuhiro Miyazaki and Tadashi Koga and Eiji Oki and Yoshihiro Kakeji and Yoshihiko Maehara",
year = "2010",
month = "11",
day = "1",
doi = "10.1007/s00595-010-4296-y",
language = "English",
volume = "40",
pages = "1034--1039",
journal = "Surgery Today",
issn = "0941-1291",
publisher = "Springer Japan",
number = "11",

}

TY - JOUR

T1 - A survey of the effects of sivelestat sodium administration on patients with postoperative respiratory dysfunction

AU - Saeki, Hiroshi

AU - Morita, Masaru

AU - Harada, Noboru

AU - Harimoto, Norifumi

AU - Nagata, Shigeyuki

AU - Miyazaki, Mitsuhiro

AU - Koga, Tadashi

AU - Oki, Eiji

AU - Kakeji, Yoshihiro

AU - Maehara, Yoshihiko

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Purpose: To clarify the clinical significance of sivelestat sodium (SIV) administration, we surveyed the status of 40 patients treated with SIV for respiratory dysfunction following surgery. Methods: The subjects were patients who received SIV administration due to systemic inflammatory response syndrome (SIRS) and respiratory dysfunction (PaO2/FIO2 ratio ≥300 mmHg) after surgery at the Department of Surgery and Science, Kyushu University, and related facilities between April and December 2008. Results: The most frequent underlying condition was perforation of the digestive tract, followed by cancer of the upper digestive organs. The main causes of SIRS were surgical stress and infection. The mean P/F ratio at the initiation of SIV administration was 185.5 ± 72.0 mmHg. The ratio increased, and the number of SIRS-related factors decreased with time after SIV administration. Sivelestat sodium was administered within 24 h after the onset of respiratory dysfunction in 87.5% of the patients, and the survival rate at 28 days after the initiation of SIV administration was 90.0%. Conclusion: Our findings suggest that multidisciplinary postoperative management, including the administration of SIV, during the early phase after the onset of respiratory dysfunction leads to improvements in respiratory function and survival.

AB - Purpose: To clarify the clinical significance of sivelestat sodium (SIV) administration, we surveyed the status of 40 patients treated with SIV for respiratory dysfunction following surgery. Methods: The subjects were patients who received SIV administration due to systemic inflammatory response syndrome (SIRS) and respiratory dysfunction (PaO2/FIO2 ratio ≥300 mmHg) after surgery at the Department of Surgery and Science, Kyushu University, and related facilities between April and December 2008. Results: The most frequent underlying condition was perforation of the digestive tract, followed by cancer of the upper digestive organs. The main causes of SIRS were surgical stress and infection. The mean P/F ratio at the initiation of SIV administration was 185.5 ± 72.0 mmHg. The ratio increased, and the number of SIRS-related factors decreased with time after SIV administration. Sivelestat sodium was administered within 24 h after the onset of respiratory dysfunction in 87.5% of the patients, and the survival rate at 28 days after the initiation of SIV administration was 90.0%. Conclusion: Our findings suggest that multidisciplinary postoperative management, including the administration of SIV, during the early phase after the onset of respiratory dysfunction leads to improvements in respiratory function and survival.

UR - http://www.scopus.com/inward/record.url?scp=78349251261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349251261&partnerID=8YFLogxK

U2 - 10.1007/s00595-010-4296-y

DO - 10.1007/s00595-010-4296-y

M3 - Article

C2 - 21046501

AN - SCOPUS:78349251261

VL - 40

SP - 1034

EP - 1039

JO - Surgery Today

JF - Surgery Today

SN - 0941-1291

IS - 11

ER -